{"id":"NCT03748823","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","officialTitle":"A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With Eculizumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-19","primaryCompletion":"2021-02-02","completion":"2023-08-31","firstPosted":"2018-11-21","resultsPosted":"2022-10-20","lastUpdate":"2024-09-19"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Ravulizumab OBDS","otherNames":[]},{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210"]}],"arms":[{"label":"Ravulizumab SC Treatment Group","type":"EXPERIMENTAL"},{"label":"Ravulizumab IV Treatment Group","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate pharmacokinetics (PK) of ravulizumab administered subcutaneously via an on-body delivery system (OBDS) compared with intravenously administered ravulizumab in adult participants with PNH who are clinically stable on eculizumab for at least 3 months prior to study entry.","primaryOutcome":{"measure":"Ctrough Serum Concentration of Ravulizumab","timeFrame":"Predose at Day 71","effectByArm":[{"arm":"Ravulizumab IV/SC Treatment Group","deltaMin":457.58,"sd":108.491},{"arm":"Ravulizumab SC/SC Treatment Group","deltaMin":578.7,"sd":140.819}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":6},"locations":{"siteCount":51,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Finland","France","Italy","Netherlands","Russia","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["36272026"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=ALXN1210-PNH-303&amp;attachmentIdentifier=429e6f23-2b5d-4a0c-bda6-c3d88e9f946c&amp;fileName=ALXN1210-PNH-303-body_CSR_Synopsis_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":45},"commonTop":["Device delivery system issue","COVID-19","Headache","Pyrexia","Diarrhoea"]}}